PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE ...

The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted ...

Days after Tatiana Schlossberg announced that she has terminal cancer, the spotlight is on the warning signs of acute myeloid leukemia (AML). John F. Kennedy’s granddaughter, 35, shared the details of ...

SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.

Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate ...

Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its ...

An immunomodulatory vaccine advancing to phase 3 trials highlights the evolving role of immune system recalibration in cancer treatment. From immunotherapy breakthroughs to early-stage scientific ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human studyCompany to present Trial in Progress ...